Loading stock data…
SGHT
$4.85+0.22 (+4.75%)
After Hours$4.85+0.00 (+0.00%)· Last close Jun 9
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sight Sciences, Inc. in the Healthcare sector is trading at $4.85 with a market capitalization of $236M. Wall Street consensus targets $8.54 (4 analysts), implying a +76.0% move over the next 12 months. The stock is currently 47% below its 52-week high of $9.24, remaining 7.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +76.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.85
Potential Downside
0%
Whystock Fair Value$4.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$8.54+76.0%
Range$5.15 – $12.00
Fundamentals
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segmen...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$236.14M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-69.11%
Volume
Today's trading volume
144,126
Recent News
Discover 3 Promising Penny Stocks With Market Caps Over $20M
Over the last 7 days, the U.S. market has dropped by 2.7%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. For investors interested in smaller or newer companies, penny stocks — despite being an older term — remain relevant as they can offer surprising value and growth potential when backed by strong financials. This article highlights several penny stocks that stand out for their financial strength, presenting opportunities for those seeking...
Sight Sciences Q1 Earnings Call Highlights
Sight Sciences (NASDAQ:SGHT) reported first-quarter 2026 results that management said marked a “strong start” to the year, highlighted by a return to double-digit revenue growth, steady gross margin performance, and lower cash usage. The company also raised its full-year 2026 revenue guidance while
Sight Sciences, Inc. Q1 2026 Earnings Call Summary
Moby summary of Sight Sciences, Inc.'s Q1 2026 earnings call
Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Sight Sciences (SGHT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +14.30% and +6.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?